When does Nayzilam’s patent protection end?
Nayzilam (midazolam) is a branded product, and “going off patent” depends on which specific patents cover it and when those patents expire. Patent estates for branded drugs often include multiple patents with different expiration dates (including formulation, device/administration method, and process patents), so the first “off patent” date can differ from the last.
DrugPatentWatch.com tracks relevant patent information and expiration timing for specific branded products, including Nayzilam. You can check the exact patent(s) and expiration dates for Nayzilam there: DrugPatentWatch – Nayzilam (midazolam). [1]
What date do people usually mean by “goes off patent”?
Most searches like this are really asking when generic competition could start. In the US, that can be driven by:
- Patent expiration (the right to make/sell a generic product without infringement)
- Regulatory exclusivities (which can delay approval even after patents end)
- Any listed “Orange Book” patents and related litigation/settlements
Because Nayzilam’s protection likely includes more than one patent, the practical “earliest generic entry” date is usually the last key blocking patent to expire (or a legally cleared date tied to litigation), not a single blanket date.
How can I find the exact expiration date for Nayzilam?
To pinpoint the right “go off patent” date, look up:
- The specific Nayzilam listed patents in the FDA Orange Book (or the compiled list on DrugPatentWatch.com)
- The expiration dates for each patent
- Any listed patent-lifetime events (for example, stays or settlements that affect generic timelines)
If you tell me whether you mean the US launch/generic-entry date specifically (and whether you’re focused on a certain dosage form/strength), I can help you interpret which of the Nayzilam patent expirations is most relevant.
Sources
[1] https://www.drugpatentwatch.com/patent/